Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $195
AbbVie Snaps Eight Straight Sessions of Losses
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA
Express News | Aldeyra Therapeutics: Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co if Option Is Exercised